MX2021002246A - Procesos para la preparacion de 4-{8-amino-3-[(2s)-1-(but-2-inoil) pirrolidin-2-il]imidazo[1,5-a]-pirazin-1-il}-n-(piridin-2-il)benz amida. - Google Patents

Procesos para la preparacion de 4-{8-amino-3-[(2s)-1-(but-2-inoil) pirrolidin-2-il]imidazo[1,5-a]-pirazin-1-il}-n-(piridin-2-il)benz amida.

Info

Publication number
MX2021002246A
MX2021002246A MX2021002246A MX2021002246A MX2021002246A MX 2021002246 A MX2021002246 A MX 2021002246A MX 2021002246 A MX2021002246 A MX 2021002246A MX 2021002246 A MX2021002246 A MX 2021002246A MX 2021002246 A MX2021002246 A MX 2021002246A
Authority
MX
Mexico
Prior art keywords
processes
pyrazin
imidazo
pyrrolidin
benzamide
Prior art date
Application number
MX2021002246A
Other languages
English (en)
Spanish (es)
Inventor
Andrew John Phillips
Rustam Ferdinand Garrey
Jerry Evarts
Paul Allen Bethel
Lai Chun Chan
Katie Grace Cooper
Robert John Cox
Michael David Golden
Shaun Alan Hughes
Lucinda Victoria Jackson
Kirsty Jane Millard
Alexander James Telford
Michael Joseph Lawler
Remy E J N Litjens
Eijk Peter Johannes Servaas Savio Van
Mathilda Maria Henrica Verstappen
Frank L M Vos
Eric Jurriën Zijp
Qiu Junying
Angang Wang
David Allen Short
Original Assignee
Acerta Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv
Publication of MX2021002246A publication Critical patent/MX2021002246A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MX2021002246A 2018-08-29 2019-08-28 Procesos para la preparacion de 4-{8-amino-3-[(2s)-1-(but-2-inoil) pirrolidin-2-il]imidazo[1,5-a]-pirazin-1-il}-n-(piridin-2-il)benz amida. MX2021002246A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862724228P 2018-08-29 2018-08-29
PCT/EP2019/072991 WO2020043787A1 (en) 2018-08-29 2019-08-28 Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide

Publications (1)

Publication Number Publication Date
MX2021002246A true MX2021002246A (es) 2021-05-27

Family

ID=67928802

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021002246A MX2021002246A (es) 2018-08-29 2019-08-28 Procesos para la preparacion de 4-{8-amino-3-[(2s)-1-(but-2-inoil) pirrolidin-2-il]imidazo[1,5-a]-pirazin-1-il}-n-(piridin-2-il)benz amida.
MX2023011692A MX2023011692A (es) 2018-08-29 2021-02-25 Procesos para la preparacion de 4-{8-amino-3-[(2s)-1-(but-2-inoil) pirrolidin-2-il]imidazo[1,5-a]-pirazin-1-il}-n-(piridin-2-il)benz amida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023011692A MX2023011692A (es) 2018-08-29 2021-02-25 Procesos para la preparacion de 4-{8-amino-3-[(2s)-1-(but-2-inoil) pirrolidin-2-il]imidazo[1,5-a]-pirazin-1-il}-n-(piridin-2-il)benz amida.

Country Status (16)

Country Link
US (3) US12024520B2 (cg-RX-API-DMAC10.html)
EP (1) EP3844149A1 (cg-RX-API-DMAC10.html)
JP (3) JP7439095B2 (cg-RX-API-DMAC10.html)
KR (2) KR20250119664A (cg-RX-API-DMAC10.html)
CN (2) CN112638878B (cg-RX-API-DMAC10.html)
AU (4) AU2019332882B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021003480A2 (cg-RX-API-DMAC10.html)
CA (1) CA3109734A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021003676A2 (cg-RX-API-DMAC10.html)
EA (1) EA202190557A1 (cg-RX-API-DMAC10.html)
IL (3) IL281025B2 (cg-RX-API-DMAC10.html)
MA (1) MA53485A (cg-RX-API-DMAC10.html)
MX (2) MX2021002246A (cg-RX-API-DMAC10.html)
MY (1) MY206899A (cg-RX-API-DMAC10.html)
WO (1) WO2020043787A1 (cg-RX-API-DMAC10.html)
ZA (2) ZA202306381B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250119664A (ko) * 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정
EP3947386A1 (en) * 2019-03-27 2022-02-09 Assia Chemical Industries Ltd Solid state forms of acalabrutinib
DK4054582T3 (da) 2019-11-04 2025-12-01 Astrazeneca Ab Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter
CR20230018A (es) 2020-06-19 2023-04-11 Acerta Pharma Bv Formas farmacéuticas de maleato de acalabrutinib

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372694T3 (es) 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
EP2139487B1 (en) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US8362249B2 (en) 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
US8658794B2 (en) 2010-02-08 2014-02-25 Merck Sharp & Dohme B.V. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof
CN103889987B (zh) * 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
MX362181B (es) 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2016128912A1 (en) 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
WO2017077507A1 (en) * 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
CN107056786B (zh) 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法
ES2856248T3 (es) 2016-12-21 2021-09-27 Acerta Pharma Bv Inhibidores de imidazopirazina de la tirosina quinasa de Bruton
WO2018115965A1 (en) * 2016-12-23 2018-06-28 Acerta Pharma Bv Solid forms of imidazopyrazine compounds
CN106588937B (zh) 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
US10899770B2 (en) 2017-02-20 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof
US10800787B2 (en) 2017-04-20 2020-10-13 Apotex Inc. Process for the preparation of acalabrutinib
CN107522701B (zh) 2017-09-01 2019-11-08 苏州富士莱医药股份有限公司 一种治疗慢性淋巴细胞白血病的BTK抑制剂Acalabrutinib的合成方法
US11161851B2 (en) 2017-11-06 2021-11-02 Suzhou Pengxu Pharmatech Co. Ltd. Processes to produce acalabrutinib
CN108250186B (zh) * 2018-02-07 2020-01-14 杭州科巢生物科技有限公司 Acalabrutinib及其中间体的合成方法
WO2019239374A1 (en) 2018-06-13 2019-12-19 Acerta Pharma B.V. Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase
KR20250119664A (ko) * 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法

Also Published As

Publication number Publication date
CA3109734A1 (en) 2020-03-05
MX2023011692A (es) 2023-10-19
US20240317766A1 (en) 2024-09-26
JP2026021364A (ja) 2026-02-10
KR20210053304A (ko) 2021-05-11
AU2023204660A1 (en) 2023-08-03
IL322382A (en) 2025-09-01
AU2023204660B2 (en) 2024-01-25
WO2020043787A1 (en) 2020-03-05
IL281025B1 (en) 2024-08-01
JP2024037935A (ja) 2024-03-19
US12448387B2 (en) 2025-10-21
AU2022200828B2 (en) 2023-05-25
KR102842131B1 (ko) 2025-08-04
CN112638878A (zh) 2021-04-09
JP2021535220A (ja) 2021-12-16
CN112638878B (zh) 2025-07-22
KR20250119664A (ko) 2025-08-07
IL281025A (en) 2021-04-29
JP7829541B2 (ja) 2026-03-13
AU2024202290A1 (en) 2024-05-02
US12024520B2 (en) 2024-07-02
IL312413A (en) 2024-06-01
CN120904205A (zh) 2025-11-07
US20260109701A1 (en) 2026-04-23
MA53485A (fr) 2021-12-08
IL312413B1 (en) 2025-09-01
ZA202306381B (en) 2024-11-27
ZA202409391B (en) 2025-04-30
EA202190557A1 (ru) 2021-07-13
CO2021003676A2 (es) 2021-04-08
AU2022200828A1 (en) 2022-03-03
EP3844149A1 (en) 2021-07-07
JP7439095B2 (ja) 2024-02-27
BR112021003480A2 (pt) 2021-05-18
AU2019332882A1 (en) 2021-04-22
AU2019332882B2 (en) 2022-01-27
IL312413B2 (en) 2026-01-01
MY206899A (en) 2025-01-13
US20220127270A1 (en) 2022-04-28
IL281025B2 (en) 2024-12-01

Similar Documents

Publication Publication Date Title
MX2023011692A (es) Procesos para la preparacion de 4-{8-amino-3-[(2s)-1-(but-2-inoil) pirrolidin-2-il]imidazo[1,5-a]-pirazin-1-il}-n-(piridin-2-il)benz amida.
SV2018005740A (es) Metodos para tratar la depresion con antagonistas del receptor de orexina-2
EA201500923A1 (ru) Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
CL2020003022A1 (es) Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
EA201270591A1 (ru) ДВУЗАМЕЩЕННЫЕ ОКТАГИДРОПИРРОЛ[3,4-c]ПИРРОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОРЕКСИНОВЫХ РЕЦЕПТОРОВ
AU2017241807A1 (en) Medium, methods, cells and secreted factors for stem cell culture and therapy
EA201170741A1 (ru) Производные n-{[(1r,4s,6r)-3-(2-пиридинилкарбонил)-3-азабицикло[4.1.0]гепт-4-ил]метил}-2-гетероариламина и их применения
CL2015002386A1 (es) Nuevos octahidro-pirrolo[3,4-c)-pirrol y -piridina-fenilo.
MX380283B (es) Compuesto de amino pirazolopirimidina usado como inhibidor del receptor de tirosina cinasa del factor neurotrófico
CR20160465A (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)
PH12018502230A1 (en) Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia
ECSP14013192A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-onas sustituidas
PH12020550537A1 (en) Bicyclic sulfones and sulfoxides and methods of use thereof
MX2020008110A (es) Sal de compuesto de pirazolo[1,5-a]pirimidina y cristales de la misma.
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
AR062114A1 (es) Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos.
PE20100084A1 (es) Combinacion farmaceutica
IN2014KN02722A (cg-RX-API-DMAC10.html)
MX2018014684A (es) Derivados de [1,2,3]triazolo[4,5-d]pirimidina con afinidad para el receptor de canabinoide de tipo 2.
PH12021550295A1 (en) Rubber mixtures
AR100821A1 (es) Pirazolil-triazolil-piridinas como agentes plaguicidas
MX2025010847A (es) Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg
PH12017501335A1 (en) Novel salt of fused pyrimidine compound and crystal thereof
HK40055116A (en) Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
AR051933A1 (es) Proceso para la preparacion de n-(3,5 dicloropirid-4-ilo)-4-difluormetoxi-8-metano sulfonamido-dibenzo[b,d] furano-1-carboxamida